Michele Basche
University of Colorado Boulder
14 Papers
148 Citations
Michele Basche is an academic researcher from University of Colorado Boulder. The author has contributed to research in topics: Pharmacokinetics & Capecitabine. The author has an hindex of 11, co-authored 14 publications. Previous affiliations of Michele Basche include University of Colorado Denver.
Chat about Author
Papers
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-β inhibitor
Lisa J. Green,Philip Marder,Chad Ray,Carolyn A. Cook,Susan Jaken,Luna Musib,Roy S. Herbst,Michael A. Carducci,Carolyn D. Britten,Michele Basche,S. Gail Eckhardt,Donald Thornton +11 more
TL;DR: An inhibition of surrogate target cell PKC activity was observed both in vitro and ex vivo after exposure to the novel kinase inhibitor, enzastaurin.
46
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies
Laura Q M Chow,Laura Q M Chow,Daniel L. Gustafson,Cindy L. O'Bryant,Lia Gore,Michele Basche,Scott N. Holden,Mark Morrow,S. Grolnic,Brian R. Creese,Kaye L. Roberts,Kat Davis,R. S. Addison,S. Gail Eckhardt +13 more
TL;DR: PI-88 administered at 250 mg/day for 4 days each week for 3 weeks with docetaxel 30 mg/m2 on days 1, 8 and 15, every 28 days, was determined to be the recommended dose level for phase II evaluation and was well tolerated without severe toxicities or PK interactions.
A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors
Laura Q M Chow,S. Gail Eckhardt,Cindy L. O'Bryant,Mary Kay Schultz,Mark Morrow,S. Grolnic,Michele Basche,Lia Gore,Lia Gore,Lia Gore +9 more
TL;DR: Despite the observed efficacy, substantial toxicity and questionable contribution of anti-tumor activity of lonafarnib to gemcitabine and cisplatin limits further exploration of this combination.
26
A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.
Samir E. Witta,Daniel L. Gustafson,A. Scott Pierson,Alexander Menter,Scott N. Holden,Michele Basche,Martha Persky,Cindy L. O'Bryant,Chan Zeng,Anna E. Barón,Michael E. Long,Amy Gibbs,Karen Kelly,Paul A. Bunn,Daniel C. Chan,Patrick Pallansch,S. Gail Eckhardt +16 more
TL;DR: The combination of docetaxel (36 mg/m2, weekly) and exisulind (500 mg/d) was reasonably well tolerated, and it is undergoing phase II testing in patients with non–small-cell lung cancer.
24
Updated results from a phase I trial of the histone deacetylase (HDAC) inhibitor MS-275 in patients with refractory solid tumors
Lia Gore,Scott N. Holden,Michele Basche,S. K. S. Raj,I. Arnold,Cindy L. O'Bryant,Samir E. Witta,B. Rohde,C. McCoy,S. G. Eckhardt +9 more
TL;DR: Inhibition of HDACs in vitro has resulted in tumor cell growth arrest, differentiation and/or tumor apoptosis and the pharmacokinetics and pharmacodynamics are evaluated.
22